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Abstract
Background: Hyperplasia of usual type (HUT) is a common proliferative lesion associated with a
slight elevated risk for subsequent development of breast cancer. Cell cycle-related proteins would
be helpful to determine the putative role of these markers in the process of mammary
carcinogenesis. The aim of this study was to analyze the expression of cell cycle related proteins in
HUT of breast specimens of patients with and without breast cancer, and compare this expression
with areas of invasive carcinomas.
Results: Immunohistochemical evaluation was performed using antibodies against cell cycle related
proteins ER, PR, p53, p21, p63, and Ki-67 in hyperplasia of usual type (HUT) in specimens of
aesthetic reduction mammaplasty (ARM), in specimens of mammaplasty contralateral to breast
cancer (MCC), and in specimens of invasive mammary carcinomas (IMC) presenting HUT in the
adjacent parenchyma. The results showed that the immunoexpression of ER, PR, p21, p53, p63, and
KI-67 was similar in HUT from the three different groups. The p63 expression in myoepithelial cells
showed discontinuous pattern in the majority of HUT, different from continuous expression in
normal lobules. Nuclear expression of p53 and p21 was frequently higher expressed in IMC and
very rare in HUT. We also found cytoplasmic expression of p21 in benign hyperplastic lesions and
in neoplastic cells of IMC.
Conclusion: Our data failed to demonstrate different expression of cell cycle related proteins in
HUT from patients with and without breast cancer. However, we found discontinuous expression
of p63 in myoepithelial cells around HUT adjacent to carcinomas and cytoplasmic expression of
p21 in epithelial cells of hyperplastic foci. Further studies are needed to determine how these
subgroups relate to molecular abnormalities and cancer risk.
Background
The hypothetical multistep model of carcinogenesis indi-
cates that breast cancer develops via a series of intermedi-
ate hyperplastic lesions through in situ to invasive
carcinomas, with the risk of developing carcinoma
increasing at each stage [1-3]. Epidemiological studies
demonstrated an increased risk of developing breast can-
cer associated with proliferative breast lesions. Hyperpla-
sia of usual type (HUT) is a common proliferative lesion
associated with a slightly elevated risk for subsequent
development of breast cancer (relative risk = 1.6, aug-
mented to 2.1 with positive family history) [1,2,4]. HUT
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is not necessarily a direct precursor of invasive breast car-
cinoma but may identify individuals whose breast tissue
has acquired a molecular alteration that can facilitate the
eventual development of this disease [5].
The defective function of regulatory cell cycle elements,
like estrogen and progesterone receptors, Ki-67, p53,
p21WAF1  and p63 leads toward increased proliferation
and, in addition, expansion of genome damaged cells.
Cell cycle-related markers would be helpful to determine
the putative role of these markers in the process of mam-
mary carcinogenesis [6].
Many studies evaluated cell cycle-related proteins in inva-
sive breast carcinomas, but there are few studies evaluat-
ing these proteins in HUT [7-9]. Some molecular
alterations may already be present in the earliest stages of
breast cancer development. Detection of these alterations
may be important for understanding the pathogenesis
and also for risk assessment of premalignant breast
lesions.
Incidental cancers or precursor lesions are rare in speci-
mens of cosmetic mammaplasty compared to reduction
mammaplasty specimens performed for symmetry of con-
tralateral breast in women with breast cancer undergoing
mastectomy or conservative surgery. Our hypothesis is
that the expression of cell cycle related proteins would be
different in HUT lesions from women at higher risk of
breast cancer or with breast cancer, compared to those
HUT from women without breast cancer. The aim of this
study is to analyze the expression pattern of cell cycle
related proteins ER, PR, p53, p21WAF1, p63, and Ki-67 in
hyperplasia of usual type (HUT) of breast specimens of
patients with and without breast cancer, and compare this
expression with neoplastic cells of invasive carcinomas.
Results
The age of patients submitted to ARM ranged from 30 to
67 years (mean 43.9 years; SD = ± 7.4 years), of patients
with IMC ranged from 30 to 86 years (mean 55. 7; SD = ±
13.1 years), and age of patients submitted to MCC ranged
from 30 to 75 years (mean 51.6; SD = ± 12.4 years).
Patients were divided according to the menopausal status
into pre-menopausal patients (≤ 50 years) and post-men-
opausal patients (> 50 years). The mean age of patients
with IMC and submitted to MCC was significantly greater
(Table 2) than patients submitted to ARM (p < 0.005).
There was no statistically significant difference between
mean age of patients from IMC and MCC groups.
The histologic review showed that HUT was associated
with other benign breast lesions in the majority of the
cases. Histologic findings were varied in ARM, MCC, and
IMC specimens. Usually, the strongest ER staining was
noted at the periphery of the hyperplastic foci (Figure 1A).
The majority of the epithelial cells of HUT in all speci-
mens showed positive staining for ER, PR, and Ki-67 (Fig-
ure 1; Table 3). The ER immunostaining was localized in
the nuclei and showed some variability in intensity even
in individual lesions of the same case.
The p63 expression was detected in the majority of the
myoepithelial cell nuclei in normal lobules and in HUT.
p63-positive cells around HUT foci occurred as a discon-
tinuous layer in 38.1% in ARM, in 73.3% in MCC, and in
64.7% of myoepithelial cells surrounding HUT adjacent
to IMC (Figure 2C and 2D). The p63 expression was con-
tinuous in myoepithelial cells of normal lobules and
ducts. There was no difference in the percentage of posi-
tive cells for ER, PR, p21WAF1, p53, p63, and KI-67 in HUT
of ARM, MCC and IMC (p > 0, 05). The mean percentage
of ER+, PR+, Ki-67+ in epithelial cells and, p63+ in
myoepithelial cells of HUT from all groups was signifi-
cantly higher than positivity in neoplastic cell of IMC
(Table 3).
Table 1: Primary antibodies, dilutions, and sources of antibodies used in immunohistochemical study
Antibody Clone Dilution Pretreatment Source/Country
ER 6F-11 1:100 Steamear/citrate Novocastra/UK
PR PgR 312 1:100 Steamear/citrate Novocastra/UK
p53 DO-7 1:500 Steamear/citrate Dakocytomation/USA
p21 4D10 1:20 Steamear/citrate Novocastra/UK
p63 4A4 1:100 Steamear/EDTA Dakocytomation/USA
Ki-67 MIB-1 1:100 Steamear/citrate Immunotech/France
Table 2: Menopausal status in patients submitted to aesthetic 
reduction mammaplasty (ARM), to mammaplasty contralateral 
to breast cancer (MCC), and patients with invasive mammary 
carcinoma (IMC)
Menopausal status ARM MCC IMC
< 50 years 30 (88.2%) 7 (46.7%) 13 (38.2%)
≥ 50 years 4 (11.8%) 8 (53.3%) 21 (61.8%)
Total 34 (100%) 15 (100%) 34 (100%)BMC Cell Biology 2006, 7:29 http://www.biomedcentral.com/1471-2121/7/29
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Usually, neoplastic cells of IMC showed intermediate to
high proliferative index of Ki-67 positivity (73.5%) com-
pared to positive cells of HUT from ARM specimens
(5.9%), MCC specimens (13.3%) and HUT-IMC (14.7%),
(Table 3). No significant difference was observed between
Ki-67 expression in cells of HUT-ARM and HUT-IMC. All
proliferative cells of HUT of the three different groups
were negative for p53.
The p21 expression in IMC was predominantly nuclear
(55.9%). Cytoplasmatic staining was seen in neoplastic
cells in 23.5% of cases (Figure 2F). Nuclear staining was
detected in cells of HUT-MCC in 2 cases (5.9%; Figure
1D) and 6 cases showed cytoplasmatic staining in hyper-
plastic cells (Figure 2E).
Discussion
The aim of this study was to determine alterations in the
expression of proteins involved in proliferation and cell
cycle in HUT cells of patients with and without invasive
breast cancer. Our analysis showed no difference in the
cell cycle related proteins immunoexpression in HUT
from the three different groups, in spite of age and meno-
pausal status. Similar results were obtained by Gobbi et al.
(2005)[7] evaluating ER expression in usual hyperplasia
without atypia of patients who developed breast cancer
compared with patients who did not.
In our study, we found that ER and PR immunoexpression
was significantly higher in HUT cells than in neoplastic
cells of IMC specimens. Even in all 16 cases of ER-negative
(A) Positive immunostaining for ER in nuclei of epithelial cells of HUT (400×); (B) Positive immunostaining for PR in nuclei of  epithelial cells of HUT (200×); (C) Positive immunostaining for p21 in nuclei of epithelial cells of HUT (400×); (D) Positive  immunostaining for Ki-67in nuclei of epithelial cells of HUT (400×) Figure 1
(A) Positive immunostaining for ER in nuclei of epithelial cells of HUT (400×); (B) Positive immunostaining for PR in nuclei of 
epithelial cells of HUT (200×); (C) Positive immunostaining for p21 in nuclei of epithelial cells of HUT (400×); (D) Positive 
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tumors the epithelial cells of HUT were positive for ER.
Our results are in agreement with other investigators who
found higher levels of ER expression in benign breast epi-
thelium of patients who developed breast cancer com-
pared to controls [7,9-11]. The presence of positive ER
staining in normal lobules increases the breast cancer risk
and the likelihood of progression to cancer [7]. It occurs
through the increase of the rate of cell proliferation by
both recruiting non-cycling cells into the cell cycle and by
shortening the overall cell cycle time due to a reduction in
the length of G1 phase [11].
Previous comparison between normal and precancerous
breast biopsies has shown that ER expression is relatively
low in normal epithelium and slightly increased in HUT
[12]. Recent studies indicate that HUT is a heterogeneous
entity containing subgroups identified according to the
criterion of ER-α (+) proliferating cells and this fact could
explain the different biologic behavior of HUT [13]. In
our study, the ER positive cells were more often found at
the periphery of hyperplastic lesions. Similar pattern of ER
positivity was previously described by Gobbi et
al(2005)[7]. It is possible that the ER+ epithelial cells at
the periphery of HUT represent the most proliferative
group of cells, in spite of low positivity for Ki-67 in
sequential sections of the same lesion. The estrogen expo-
sure may stimulate a clonal proliferation of some ER+
cells or may increase the chance of spontaneous muta-
tions [9].
In normal breast, there is a negative association between
expression of ER and Ki-67, indicating either that ER+
cells are non-dividing or that the receptor is down-regu-
lated as cells enter cycle [12,14]. This important correla-
tion breaks down in many ER+ cancers, where the receptor
is often detected in proliferating cells [14]. However, cells
co-expressing ER-α and Ki-67 have been found in precan-
cerous lesions and correlate positively with the level of
risk of developing breast cancer [11]. In our series, we
found higher ER and Ki-67 immunoexpression in HUT
areas compared to the immunopositivity for these mark-
ers in adjacent normal lobules. Our results are similar to
those described by Schmitt (1995) [11] who found the
existence of a positive correlation between ER status and
proliferation in hyperplasic epithelium and a progressive
inversion of this relationship in lesions evolving towards
malignancy. The observation of higher rates of prolifera-
tion in ER positive benign proliferative breast lesions fits
with the concept of an initial hormone-dependent status
in breast carcinogenesis [11]. In addition, HUT with
higher expression of ER and Ki-67 could represent a subset
of hyperplastic lesions with increased risk of subsequent
breast cancer development.
Some previous studies suggest that at least some HUTs are
clonal [9,15]. Nevertheless, it remains unclear whether
the dysregulation of ER has arisen prior to clonal expan-
sion of the HUT, since cells with apparently abnormal reg-
ulation of ER during cell division are scattered randomly
throughout the HUT in a non-contiguous pattern in some
cases. The variable number of ER+ cells might indicate
that in HUT the dysregulation of ER expression is incom-
plete and may be absent in some lesions, or apparent
under certain conditions [13].
We detected p53 and p21 positivity in neoplastic cells of
IMC, especially in high grade carcinomas. Mutations in
tumor suppressor gene TP53, which mediates G1 arrest
and apoptosis leads to an increased half-life and accumu-
lation of the p53 protein [16]. A way to investigate the
functional status of TP53 is to evaluate some of its down-
stream effectors such as p21 gene whose product acts by
blocking cyclin-dependent kinases [17]. In our study, we
found a positive association between expression of p21
Table 3: Positivity for ER, PR, p53, p21, p63, and KI-67 in HUT areas of reduction aesthetic mammaplasty specimens (HUT-ARM), 
HUT of mammaplasty contralateral to breast cancer (HUT-MCC); HUT adjacent to invasive mammary carcinoma (HUT-IMC), and in 
invasive mammary carcinoma (IMC)
Antibody HUT-ARM n (%) HUT-MCC n (%) HUT-IMC n (%) IMC n (%)
RE 33 (97.1) 13 (86.7) 32 (94.1) 18 (52.9)
RP 34 (100) 12 (80,0) 33 (97.1) 18 (52.9)
p53 0 (0) 0 (0) 0 (0) 19 (55.9)
p21 0 (0) 0 (0) N*- 2 (5.9) N*- 19 (55.9)
C*- 6 (17.6) C*- 8 (23.5)
p63 34 (100) 15 (100) 34 (100) 3 (8.8)
Ki-67 ** L- 20 (58.8) L- 4 (26.7) L- 22 (64.7) L- 9 (26.5)
I- 2 (5.9) I- 2 (13.3) I- 5 (14.7) I- 17 (50)
H- 8 (23.5)
* Localization of p21 staining: N- nuclear, C- cytoplasmatic
** KI-67 expressed as: L-low, I-intermediate, and H-high proliferative indexBMC Cell Biology 2006, 7:29 http://www.biomedcentral.com/1471-2121/7/29
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Positive immunostaining for ER (400×) (A) and for Ki-67 (400×) (B) in nuclei of epithelial cells of HUT, note in both the marked  staining of the most of the cells at the periphery of the spaces Figure 2
Positive immunostaining for ER (400×) (A) and for Ki-67 (400×) (B) in nuclei of epithelial cells of HUT, note in both the marked 
staining of the most of the cells at the periphery of the spaces. Positive immunostaining for p63 in nuclei of myoepithelial cells 
of HUT occurred as a continuous layer (C) (200×); and occurred as a discontinuous layer pattern (200×)(D)in nuclei of 
myoepithelial cells of HUT. Positive immunostaining for p21in cytoplasm of epithelial cells of HUT (400×) (E) and in invasive 
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and p53 in neoplastic cells, which is in agreement with the
studies of Bankfalvi et al (2000)[18] and Pelikainen et al
(2003)[19].
High expression of p21 would result in decreased cell pro-
liferation subsequent to inhibition of cyclin/CDK activity
[20]. However, in our study p21 expression in neoplastic
cells was related to higher proliferative index. Our results
are in agreement with the theory of p53 independent
pathways of p21 regulation in breast cancer [21,22]. High
amounts of p21 in high proliferating cells may reflect an
unsuccessful effort to halt proliferation. This may result
from the presence of other cell cycle regulatory pathways,
which bypass the p21 mediated cell cycle block, such as c-
Myc or B-myb [17] or due to mutant non-functional
forms of p21 which posses prolonged half lives [23]. In
addition, p21 expression can indeed be up-regulated by
epidermal growth factor receptor and transforming
growth factor β1 [17] which are associated with higher
tumor grade and disease progression in breast carcinoma
[24,25].
In our study, cytoplasmic expression of p21 was found in
17.6% of benign hyperplastic cells and in 23.5% of neo-
plastic cells of IMC. Previous studies have reported exclu-
sive nuclear localization of p21 in neoplastic cells of
breast carcinomas [19,23], and in epithelial cells of HUT
[8] However, other authors reported p21 immunoexpres-
sion in the cytoplasm of breast and ovarian tumors and it
was considered critical for promoting cell transformation
[26,27]. There is no other data in current literature con-
cerning cytoplasmatic p21 expression in HUT similar to
our findings. It remains unclear how the elevated cyto-
plasmic p21 expression might contribute to tumorigene-
sis. One possibility is that p21 is sequestered away from
the nucleus thereby preventing it from binding to nuclear
cyclin/CDK complexes, thus allowing sufficient cyclin/
CDK activity for cell cycle progression [28]. Alternately,
relocalization of p21 to the cytoplasm may target cyto-
plasmic molecules such as apoptosis signal-regulating
kinase 1 (ASK1) thereby promoting cell survival [29].
In our study, p63 was exclusively expressed in myoepithe-
lial cells of normal breast lobules and ducts, partially
expressed around the HUT cells, and rarely expressed in
invasive breast carcinoma. We observed that p63 staining
was discontinuous in 38.1% in HUT-ARM, in 73.3% in
HUT-MCC, and in 64.7% in HUT-IMC. The discontinu-
ous p63 expression pattern in HUT was different from
continuous expression in normal lobules and could sug-
gest that there is loss of p63 expression in the progression
to invasive carcinoma. Our data is similar to the findings
of Wang et al (2002)[30] that demonstrate non-continu-
ous expression of p63 in usual ductal hyperplasia. P63
expression has been useful to differentiate DCIS from
microinvasive and invasive carcinomas based on lack of
myoepithelial cells in invasive tumors without continu-
ous distribution [31-33]. Although p63 is the most spe-
cific marker for myoepithelial cells, limitations exist
because discontinuous myoepithelial layer seen in benign
lesions, such as in our study may potentially cause diag-
nostic problems in clinical practice [34].
Although our data and genetic studies failed to demon-
strate molecular changes in HUT, that are present in
columnar cell lesions, ADH cells and in neoplastic cells of
DCIS and IMC [36] the argument that HUT may be an
early precursor is still supported by consistent data from
epidemiological studies [1-4,37,38].
Conclusion
Our findings and previously published data [36,37] dem-
onstrate that the imunoprofile of HUT is different from
other accepted precursor lesions, since they are composed
of a mixed population of cells types with variable propor-
tions of cell-cycle related protein expression, and some
alterations could be present in the latest stages of breast
cancer development.
Methods
We selected slides and formalin-fixed, paraffin-embedded
blocks from 83 female mammary specimens examined in
the Breast Pathology Laboratory of Hospital das Clínicas
of Federal University of Minas Gerais received from 1996
to 2004. The specimens selected were 34 specimens of aes-
thetic reduction mammaplasty (ARM), 15 specimens of
mammaplasty contralateral to breast cancer (MCC), and
34 specimens of invasive mammary carcinomas (IMC)
presenting HUT in the adjacent parenchyma. The aes-
thetic reduction mammaplasty was indicated only for cos-
metic reasons or for back pain related to hypertrophic
breast. There was no clinic or mammography alteration in
the breasts of these patients. The mammaplasties contral-
ateral to breast cancer were indicated in order to obtain an
aesthetic balance and equilibrium related to the contralat-
eral lumpectomy or mastectomy indicated because of
breast cancer. Clinical and pathological data were
obtained from the Breast Pathology Laboratory and hos-
pital files. Clinical features evaluated were age, and men-
opausal status. Slides were reviewed by two observers and
criteria used to classify HUT were those from Page &
Anderson (1987)[39] and the terminology adopted by the
WHO classification [40]. We performed immunostainings
using monoclonal antibodies (summarized in Table 1)
and the streptavidin-biotin method (Biogenex, USA) with
previous heat-induced epitope retrieval. Immunoreactiv-
ity for ER, PR, p53, p21WAF1, p63, and Ki-67 was evaluated
in HUT of ARM specimens (HUT-ARM), in HUT of MCC
specimens (HUT-MCC), in HUT adjacent to invasiveBMC Cell Biology 2006, 7:29 http://www.biomedcentral.com/1471-2121/7/29
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mammary carcinomas (HUT-IMC), and in neoplastic cells
of IMC specimens.
Only nuclear staining was considered in the evaluation of
ER, PR, p53, p63, and KI-67. For p21WAF1, both nuclear
and cytoplasmatic staining were considered positive [35].
We also evaluated ER expression in normal lobules of
ARM and MCC specimens, and in adjacent normal lob-
ules of IMC. Two to four lobular units adjacent to HUT
areas were evaluated in each case.
Cases were classified as ER, PR, and p53 positive when
more than 10% of cells exhibited positive nuclear staining
[7,41,42]. The Ki-67 labeling index was obtained by the
percentage of neoplastic and HUT cells showing nuclear
staining. The tumors and HUT were grouped in three cat-
egories: < 10%, low proliferative index; 10–25%, interme-
diate proliferative index; and > 25%, high proliferative
index [43]. We considered p63 positive cases when at least
10% of myoepithelial cells exhibited positive nuclear
staining [32]. Cases were classified as p21WAF1 positive
when more than 2% of cells exhibited positive nuclear
staining [35].
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MCC- mammaplasty contralateral to breast cancer
IMC- invasive mammary carcinomas
ARM- aesthetic reduction mammaplasty
HUT-ARM- hyperplasia of usual type in aesthetic reduc-
tion mammaplasty
HUT-MCC in mammaplasty contralateral to breast cancer
HUT-IMC in invasive mammary carcinomas
WHO- world health organization
DCIS- ductal carcinoma in situ
ADH- atypical ductal hyperplasia
G1- cell cycle phase gap 1
Authors' contributions
LSAT: obtained the samples, carried out the histopatho-
logical and immunohistochemical analysis and wrote the
first draft of manuscript. GFSR: carried out the histology
and immunohistochemistry. HG: conceived and designed
the study, confirmed the histopathological and immuno-
histochemical analysis and provided expert input for writ-
ing and supervised the study.
All authors have read and approved the final manuscript.
Acknowledgements
Supported by grants from Fundação de Amparo à Pesquisa do Estado de 
Minas Gerais (FAPEMIG; CDS 560/01) and Conselho Nacional de Desen-
volvimento Científico e Tecnológico (CNPq; 520117/00-0 NV)
We thank Sandra J. Olson for revising the English manuscript.
References
1. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and pre-
dictive factors in breast cancer by immunohistochemical
analysis.  Mod Pathol 1998, 11:155-68.
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen
AL: Prognostic significance of TP53 alterations in breast car-
cinoma.  Br J Cancer 1993, 68:540-8.
3. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K,
Mizutani S: Apoptosis inhibitory activity of cytoplasmic
p21(Cip1/WAF1) in monocytic differentiation.  Embo J 1999,
18:1223-34.
4. Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba
C, Fuzesi L, Lelle RJ, Bocker W: Clinical relevance of immunohis-
tochemical expression of p53-targeted gene products mdm-
2, p21 and bcl-2 in breast carcinoma.  Pathol Res Pract 2000,
196:489-501.
5. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F,
Leek R, Morelli L, Leonardi E, Bevilacqua G, et al.: p21WAF1 immu-
nohistochemical expression in breast carcinoma: correla-
tions with clinicopathological data, oestrogen receptor
status, MIB1 expression, p53 gene and protein alterations
and relapse-free survival.  Br J Cancer 1996, 74:208-15.
6. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Dog-
lioni C: p63, a p53 homologue, is a selective nuclear marker
of myoepithelial cells of the human breast.  Am J Surg Pathol
2001, 25:1054-60.
7. Barboule N, Baldin V, S JO, Vidal S, Valette A: Increased level of
p21 in human ovarian tumors is associated with increased
expression of cdk2, cyclin A and PCNA.  Int J Cancer 1998,
76:891-6.
8. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta
F, Fina P, Leek R, Morelli L, Palma PD, et al.: Prognostic value of
p21(WAF1) and p53 expression in breast carcinoma: an
immunohistochemical study in 261 patients with long-term
follow-up.  Clin Cancer Res 1996, 2:1591-9.
9. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation
between steroid receptor expression and cell proliferation in
the human breast.  Cancer Res 1997, 57:4987-91.
10. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transform-
ing growth factor beta induces the cyclin-dependent kinase
inhibitor p21 through a p53-independent mechanism.  Proc
Natl Acad Sci U S A 1995, 92:5545-9.
11. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Feldstein-
Teruya J, Pohar K, Hoos A, Cordon-Cardo C: p63 expression pro-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cell Biology 2006, 7:29 http://www.biomedcentral.com/1471-2121/7/29
Page 8 of 8
(page number not for citation purposes)
files in human normal and tumor tissues.  Clin Cancer Res 2002,
8:494-501.
12. Dupont WD, Page DL: Risk factors for breast cancer in women
with proliferative breast disease.  N Engl J Med 1985, 312:146-51.
13. Elston CW, Ellis IO: Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up. C.
W. Elston & I. O. Ellis. Histopathology 1991; 19; 403–410.  His-
topathology 2002, 41:151.
14. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM,
Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al.: Prognostic fac-
tors in breast cancer. College of American Pathologists Con-
sensus Statement 1999.  Arch Pathol Lab Med 2000, 124:966-78.
15. Gobbi H, Dupont WD, Parl FF, Schuyler PA, Plummer WD, Olson SJ,
Page DL: Breast cancer risk associated with estrogen recep-
tor expression in epithelial hyperplasia lacking atypia and
adjacent lobular units.  Int J Cancer 2005, 113:857-9.
16. Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf T:
p21(waf) correlates with DNA replication but not with prog-
nosis in invasive breast cancer.  J Clin Pathol 2001, 54:866-70.
17. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohis-
tochemical staining for transforming growth factor beta 1
associates with disease progression in human breast cancer.
Cancer Res 1992, 52:6949-52.
18. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh
K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, et al.: Benign
breast disease and the risk of breast cancer.  N Engl J Med 2005,
353:229-37.
19. Iqbal M, Davies MP, Shoker BS, Jarvis C, Sibson DR, Sloane JP: Sub-
groups of non-atypical hyperplasia of breast defined by pro-
liferation of oestrogen receptor-positive cells.  J Pathol 2001,
193:333-8.
20. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estro-
gen receptor expression in benign breast epithelium and
breast cancer risk.  J Natl Cancer Inst 1998, 90:37-42.
21. Krishnamurthy S, Sneige N: Molecular and biologic markers of
premalignant lesions of human breast.  Adv Anat Pathol 2002,
9:185-97.
22. Lakhani SR, Collins N, Stratton MR, Sloane JP: Atypical ductal
hyperplasia of the breast: clonal proliferation with loss of
heterozygosity on chromosomes 16q and 17p.  J Clin Pathol
1995, 48:611-5.
23. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M,
Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al.: Prediction of
BRCA1 status in patients with breast cancer using estrogen
receptor and basal phenotype.  Clin Cancer Res 2005, 11:5175-80.
24. London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study
of benign breast disease and the risk of breast cancer.  Jama
1992, 267:941-4.
25. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ,
Colditz GA: Risk of breast cancer associated with atypical
hyperplasia of lobular and ductal types.  Cancer Epidemiol Biomar-
kers Prev 1997, 6:297-301.
26. Melo E, Alves V: Determinação da fraçãode proliferação celu-
lar no câncer de mama pela marcação imunoistoquímica do
antígeno nuclear Ki-67: comparação quantitativa e semi-
quantitativa.  J Bras Patol 1999, 35:2000.
27. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP: Expres-
sion of proliferation and apoptosis-related proteins in usual
ductal hyperplasia of the breast.  Hum Pathol 1998, 29:1539-45.
28. Orend G, Chiquet-Ehrismann R: Adhesion modulation by antiad-
hesive molecules of the extracellular matrix.  Exp Cell Res 2000,
261:104-10.
29. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK,
Eskelinen MJ, Kosma VM: p21WAF1 expression in invasive
breast cancer and its association with p53, AP-2, cell prolif-
eration, and prognosis.  J Clin Pathol 2003, 56:214-20.
30. Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta
C, Bal de Kier Joffe E, Puricelli L: Prognostic value of cell cycle
regulator molecules in surgically resected stage I and II
breast cancer.  Oncol Rep 2004, 12:1143-50.
31. Reis-Filho JS, Schmitt FC: Taking advantage of basic research:
p63 is a reliable myoepithelial and stem cell marker.  Adv Anat
Pathol 2002, 9:280-9.
32. Rey MJ, Fernandez PL, Jares P, Munoz M, Nadal A, Peiro N, Nayach I,
Mallofre C, Muntane J, Campo E, et al.: p21WAF1/Cip1 is associ-
ated with cyclin D1CCND1 expression and tubular differen-
tiation but is independent of p53 overexpression in human
breast carcinoma.  J Pathol 1998, 184:265-71.
33. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud F,
Zucoloto S: p63 correlates with both BRCA1 and cytokeratin
5 in invasive breast carcinomas: further evidence for the
pathogenesis of the basal phenotype of breast cancer.  His-
topathology 2005, 47:458-66.
34. Schmitt FC: Multistep progression from an oestrogen-depend-
ent growth towards an autonomous growth in breast car-
cinogenesis.  Eur J Cancer 1995, 31A:2049-52.
35. Schnitt SJ: Benign breast disease and breast cancer risk: mor-
phology and beyond.  Am J Surg Pathol 2003, 27:836-41.
36. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP,
Sibson DR, Sloane JP: Estrogen receptor-positive proliferating
cells in the normal and precancerous breast.  Am J Pathol 1999,
155:1811-5.
37. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution
of breast cancer.  J Pathol 2005, 205:248-54.
38. Tavassoli FA, Norris HJ: A comparison of the results of long-
term follow-up for atypical intraductal hyperplasia and intra-
ductal hyperplasia of the breast.  Cancer 1990, 65:518-29.
39. Tavassoli FA, Schnitt S, Hoefler H, Boecker W, Rosai J, Heywang-
Köbrunner H, Monfair RF, Ellis IO, Lakhani SR: Intraductal prolif-
erative lesions.  In World Health Organization Classification of Tumors.
Pathology and Genetics of Tumors of Breast Female Genital Organs Edited
by: Tavassoli FA, Devilee P. Lion: IARC Press; 2003:63-75. 
40. Thor AD, Liu S 2nd, Moore DH, Shi Q, Edgerton SM: p(21WAF1/
CIP1) expression in breast cancers: associations with p53
and outcome.  Breast Cancer Res Treat 2000, 61:33-43.
41. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai
T, Kakudo K: p63 expression in normal, hyperplastic and
malignant breast tissues.  Breast Cancer 2002, 9:216-9.
42. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cyto-
plasmic p21WAF1/CIP1 expression is correlated with HER-
2/neu in breast cancer and is an independent predictor of
prognosis.  Breast Cancer Res 2003, 5:R242-9.
43. Yang A, Kaghad M, Caput D, McKeon F: On the shoulders of
giants: p63, p73 and the rise of p53.  Trends Genet 2002, 18:90-5.